UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
Date of Report: June 5, 2023
Commission File Number: 001-39307
Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)
2101 Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Legend Biotech Announces Results from Phase 3 CARTITUDE-4 study, evaluating ciltacabtagene autoleucel (cilta-cel) for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma
On June 5, 2023, Legend Biotech Corporation (“Legend Biotech” or the “Company”) issued a press release announcing that the results from the Phase 3 CARTITUDE-4 study, evaluating ciltacabtagene autoleucel (cilta-cel) for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma who have received one to three prior lines of therapy, demonstrated an improvement in progression-free survival (PFS) compared to standard-of-care (SOC) therapy, which is attached to this Form 6-K as Exhibit 99.1 and is incorporated herein by reference.
The Company also hosted an investor event to present this data at 7am Central Time on June 5, 2023, which was also available for participation via webcast on the Company’s investor relations site under events and presentations: https://investors.legendbiotech.com/events-and-presentations.
This report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-272222, 333-257609 and 333-257625) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.
Exhibit Title
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| LEGEND BIOTECH CORPORATION | |||
Date: June 5, 2023 | By: | /s/ Ying Huang | |
Name: | Ying Huang, Ph.D. | ||
Title: | Chief Executive Officer | ||